In a statement filed with the FDA on March 19, the Center for Responsible Nutrition, which represents the US dietary supplement industry, took issue with the FDA's current proposal to revoke permission for companies to use heart health claims for soy protein products. The Natural Products Association took a similar stance. Both groups said a careful analysis of scientific studies shows that soy protein can lead to a favorable effect on LDL cholesterol and thus an improvement in heart health. Last October, in contrast, the FDA proposed revoking the claim. "We are concerned that FDA's proposal to revoke the regulation authorizing the use of the claim is inconsistent with evaluations by other international regulatory bodies, most recently Health Canada," the CRN wrote.